« Back
Home /
Tazemetostat

Tazemetostat

Item no.	HY-13803-200mg
Manufacturer	MedChem Express
CASRN	1403254-99-8
Amount	200 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.93
Citations	[1]Knutson SK, et, al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferaseEZH2. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7. Acta Pharmacol Sin. 2019 Dec;40(12):1587-1595. \|Adv Funct Mater. 2024 Jun 20.\|Apoptosis. 2020 Oct;25(9-10):697-714.\|Biomaterials. 2022 Dec 7;293:121952.\|bioRxiv. 2021 Feb 25.\|bioRxiv. 2021 Jan 1.\|bioRxiv. 2023 Jun 8.\|biorxiv. 2024 Jun 08.\|bioRxiv. 2024 September 11.\|bioRxiv. 2025 February 12.\|bioRxiv. April.\|bioRxiv. May 31, 2022.\|Cancer Lett. 2021 Oct 13;S0304-3835(21)00520-6.\|Cancer Res. 2019 Oct 1;79(19):4814-4827.\|Cancers (Basel). 2023 Jun 3, 15(11), 3043.\|Cancers (Basel). 2024 Aug 7;16(16):2785.\|Cell Death Dis. 2022 Feb 15;13(2):155.\|Cell Death Dis. 2024 Nov 8;15(11):801.\|Cell Mol Life Sci. 2024 Oct 5;81(1):417.\|Cell Prolif. 2021 May 24;e13072.\|Cell Rep. 2020 Jan 28;30(4):1223-1234.e8.\|Cell Rep. 2024 Apr 23;43(4):114090.\|Cell Rep. 2025 Jan 11;44(1):115171.\|Cell Rep. 2019 Oct 8;29(2):249-257.e8. \|Cell Rep. 2020 Jan 28;30(4):1223-1234.e8.\|Cell Stem Cell. 2025 Feb 21:S1934-5909(25)00041-4.\|Clin Transl Med. 2024 Jun;14(6):e1692.\|Elife. 2021 May 27;10:e67452.\|EMBO Rep. 2020 Jun 4;21(6):e49708.\|Epigenomics. 2025 Jan 29:1-10.\|Eur J Cell Biol. 2022 May 20;101(3):151238.\|Eur J Med Chem. 2023 Oct 2, 115825.\|Exp Eye Res. 2021 May 13;108611.\|Front Immunol. 26 May 2022.\|Heliyon. 2023 Oct 3.\|Indiana University. 2024.\|Int J Clin Oncol. 2019 Sep;24(9):1020-1029. \|J Biol Chem. 2024 Sep 12:107765.\|J Cell Mol Med. 2020 Mar;24(6):3336-3345.\|J Cell Mol Med. 2020 Sep;24(18):10648-10662.\|J Clin Invest. 2018 Jan 2;128(1):483-499. \|J Med Chem. 2021 Oct 19.\|Medicines (Basel). 2019 Jun 27;6(3):71. \|Mol Cell. 2022 Sep 29;S1097-2765(22)00896-6.\|Mol Oncol. 2018 Feb;12(2):180-195.\|Mol Syst Biol. 2023 Dec 18.\|Nat Commun. 2023 Jan 20;14(1):336.\|Nat Commun. 2023 Jul 17;14(1):4259.\|Nat Commun. 2019 Jul 1;10(1):2901. \|Nat Med. 2017 Nov;23(11):1352-1361.\|Nat Struct Mol Biol. 2018 Mar;25(3):225-232.\|Nature. 2022 Apr;604(7904):160-166.\|NPJ Breast Cancer. 2023 Aug 11;9(1):66.\|NPJ Precis Oncol. 2025 Mar 13;9(1):74.\|Oncogene. 2021 Apr;40(15):2711-2724.\|Oncotarget. 2016 Jul 19;7(29):46448-46465. \|Patent. US20180263995A1.\|Patent. US20240252638A1.\|Patent. US20240390379A1.\|PLoS One. 2025 Feb 10;20(2):e0316716.\|PLoS Pathog. 2020 Mar 24;16(3):e1008429.\|Research Square Preprint. 2024 Feb 7.\|Sci Rep. 2020 Sep 16;10(1):15201.\|Toxins (Basel). 2017 May 16;9(5). pii: E162. \|Università degli Studi di CAGLIARI. Dipartimento di Scienze Biomediche. 2021 May.\|University of Kentucky. 2023 Aug 20.\|University of Kentucky. Toxicology and Cancer Biology. 2021 May.\|Utrecht University. 2023 Feb.\|Adv Sci (Weinh). 2022 Oct 18;e2203088.
Smiles	O=C(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=CC(N(CC)C4CCOCC4)=C1C)NCC5=C(C)C=C(C)NC5=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	EPZ-6438,E-7438
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Histone Methyltransferase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	572.74
Product Description	Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 58.33 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Epigenetics
Isoform	EZH2
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13803-200mg-safety-datasheet.pdf